Sudo and Schnell Korea reported business losses.

Published: 2003-12-30 07:00:00

Updated: 2003-12-30 07:00:00

During the shareholder's meeting of the pharmaceutical companies for the fiscal year ended in Sept. 30 (Oct. 1, 2002 to Sept. 30, 2003), Sudo pharmaceutical company reported 16,160 million won of sales and losses in ordinary and net profits at their 37th shareholder's meeting on Dec. 24.

Shin...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK